CANF = MC $10 M --3x Phase 3 -- Phase 2 Data of NASH trial imminent =BIG OPP

Discussion in 'Stock picks and trading strategies' started by DollarChamp, Jan 13, 2020.

  1. DollarChamp

    DollarChamp Member

    Market Cap $10 M -- Cash $7 M-- Shares Out 4.7 M --NASH Phase 2 results imminent ($35+ BILLION MKT with no approved treatment to date -- Additional 3 Phase 3 programs in different indications ongoing .. this low float could be the next 10 bagger and even then it would be cheap if everything goes well .

    Market Cap $10 M
    Cash $7.1 M
    Price $2.72

    Shares Out 4.7 M


    Letter to Shareholders

    Q1 2020: Topline results from NASH Phase II study expected

    Advanced stage clinical pipeline positioned to potentially generate more non-dilutive funding through out-licensing distribution agreements

    Two Phase III studies enrolling in psoriasis and rheumatoid arthritis

    Advanced Stage Drug Maker in Multi-Billion Dollar Market Receives Buy Rating & $9 Price Target from Dawson James


Share This Page